Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6602858.pdf
Reference47 articles.
1. A'Hern RP, Ebbs SR, Baum MB (1988) Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 57: 615–618
2. Ackland S, Anton A, Breitbach GP, Colajori E, Tursi JM, Delfino C, Efremidis A, Ezzat A, Fittipaldo A, Kolaric K, Lopez M, Viaro D (2001) Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study. J Clin Oncol 19(4): 943–953
3. Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, Korzun A, Ginsberg S, Holland JF (1987) Chemotherapy vs chemoimmunotherapy (CAF v CAFVP v CMF each±MER) for metastatic carcinoma of the breast: a CALGB study. J Clin Oncol 5(10): 1523–1533
4. Alonso MC, Tabernero JM, Ojeda B, Llanos M, Sola C, Climent MA, Segui MA, Lopez JJ (1995) A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5- fluorouracil (CNF) vs cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Breast Cancer Res Treat 34: 15–24
5. Bennett JM, Muss HB, Doroshow JH, Wolff S, Krementz ET, Cartwright K, Dukart GD, Reisman A, Schoch I (1988) A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 6(10): 1611–1620
Cited by 58 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls;Current Opinion in Oncology;2023-07-24
2. Correlation between recurrence-free survival and overall survival after upfront surgery for resected colorectal liver metastases;British Journal of Surgery;2023-05-17
3. Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer;Frontiers in Oncology;2023-05-02
4. Survival and prognostic factors in oligometastatic breast cancer;The Breast;2023-02
5. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings;BMC Cancer;2022-09-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3